

STATEMENT ON A NONPROPRIETARY NAME ADOPTED BY THE USAN COUNCIL

USAN (GH-86) TAFASITAMAB

PRONUNCIATION ta" fa sit' a mab

THERAPEUTIC CLAIM Treatment of CD19-positive hematologic malignancies

CHEMICAL NAMES

1. Immunoglobulin, anti-(human CD19 antigen) (human-Mus musculus monoclonal MOR00208 heavy chain), disulfide with human-Mus musculus monoclonal MOR00208 κ -chain, dimer
2. immunoglobulin G1-G2-kappa, anti-(*Homo sapiens* B-lymphocyte antigen CD19 (B-lymphocyte surface antigen B4, T-cell surface antigen Leu-12)); monoclonal antibody; γ 1- γ 2 heavy chain (1-451) [VH (*Mus musculus*IGHV1-14*01 (78%) –(IGHD)-IGHJ4*01 (92%))/(*Homo sapiens* IGHV1-3*01 (74%) –(IGHD)-IGHJ4*01)] [8.8.14] (1-121) -*Homo sapiens* IGHG1*01 {CH1, hinge, CH2(1-6)} (122-240) -*Homo sapiens* IGHG2*01 {CH2(7-110)[S⁹>D(243), G⁹⁷>A(331), I¹⁰²>E(336)], CH3} (241-451) (224-219')-disulfide with κ light chain (1'-219') [V-KAPPA (*Mus musculus* IGKV2-137*01 (75%) – IGKJ2*03 (91%)/*Homo sapiens* IGKV3D-11*03 (74%) –IGKJ2*01 (91%)] [11.3.9] (1'-112') -*Homo sapiens* IGKC*01 (113'-219')], dimer (230-230":233-233")-bisdisulfide

STRUCTURAL FORMULA

Heavy chain							
EVQLVESGGG	LVKPGGSLKL	SCAASGYTFT	SYVMHWVRQA	PGKGLEWIGY	50		
INPYNDGTKY	NEKFQGRVTI	SSDKSISTAY	MELSSLRSED	TAMYYCARGT	100		
YYYGTRVFDY	WGQGLVTVS	SASTKGPSVF	PLAPSSKSTS	GGTAAALGCLV	150		
KDYFPEPVTV	SWNSGALTS	VHTFPAVLQS	SGLYSLSSVV	TVPSSSLGTQ	200		
TYICNVNHKP	SNTKVDKKE	PKSCDKTHTC	PPCPAPELLG	GPDVFLFPPK	250		
PKDTLMISRT	PEVTCVVVDV	SHEDPEVQFN	WYVDGVEVHN	AKTKPREEQF	300		
NSTFRVSVL	TVVHQDWLNG	KEYKCKVSNK	ALPAPEEKTI	SKTKGQPREP	350		
QVYTLPPSRE	EMTKNQVSLT	CLVKGFPYPS	IAVEWESNGQ	PENNYKTPP	400		
MLDSDGSFFL	YSKLTVDKSR	WQQGNVFSCS	VMHEALHNHY	TQKSLSLSPG	450		
K					451		
Light chain							
DIVMTQSPAT	LSSLSPGERAT	LSCRSSKSLQ	NVNGNTYLYW	FQKPGQSPQ	50'		
LLIYRMSNLN	SGVPRDFSGS	GSSTFTFTLI	SSLEPEDFAV	YYCMQHLEYP	100'		
ITFGAGTKLE	IKRTVAAPSV	FIFPPSDEQL	KSGTASVCL	LNNFYYPREAK	150'		
VQWQVDNALQ	SGNSQESVTE	QDSKDYSTSL	SSTLTLSKAD	YEKHKVYACE	200'		
VTHQGLSSPV	TKSFNRGEC				219'		
Disulfide bridges location							
22-96	22"-96"	23'-93'	23"-93"	139'-199'	139"-199"	148-204	148"-204"
219'-224	219"-224"	230-230"	233-233"	265-325	265"-325"	371-429	371"-429"
Glycosylation sites (N)							
Asn-301	Asn-301"						

MOLECULAR FORMULA	C ₆₅₅₀ H ₁₀₀₉₂ N ₁₇₂₄ O ₂₀₄₈ S ₅₂ (non-glycosylated)
MOLECULAR WEIGHT	147.4 kDa (non-glycosylated)
TRADEMARK	None as yet
SPONSOR	MorphoSys AG
CODE DESIGNATIONS	MOR00208, MOR208, XmAb5574
<u>CAS</u> REGISTRY NUMBER	1422527-84-1
UNII	QQA9MLH692
WHO NUMBER	10835

gbk